BRAF and non-small cell lung carcinoma: More recently, BRAF mutations—responsible for the constitutive activation of mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase (ERK) pathway—have emerged as a novel molecular target in around 2% of NSCLC patients [3, 4].